MindRank Secures Fifty-Two Million Series B for Oral GLP-1 Candidate
MindRank, a drug discovery company that uses artificial intelligence, recently completed a fifty-two million dollar Series B financing round. The company plans to use this capital to scale its Molecule Arts Platform. Additionally, the funding will help advance the company’s clinical pipeline. This computational platform combines biological, chemical, and clinical data into a learning research engine.
The system intends to make drug discovery more predictable and cost-effective. The company’s lead candidate, MDR-001, is a primary focus. This candidate is an oral small-molecule glucagon-like peptide-1 receptor agonist. These therapies mimic a natural gut hormone that controls insulin secretion and appetite.
These mechanisms support established uses in managing type 2 diabetes and obesity. The lead candidate entered Phase III development last year with a specific trial identifier. Notably, the molecule moved from initiation to Phase III in four and a half years. The company attributes this quick timeline to its computational discovery method.
Total research and development costs for the candidate reached twenty-three million dollars. Executives view this Phase III milestone as proof of the company’s strategy. Building on this success, the company has received three investigational new drug clearances. These clearances allow the company to begin human clinical trials with federal regulators.
Furthermore, the company has nominated five additional preclinical candidates. These programs show that the platform is applicable across various stages of development. Meanwhile, oral formulations are gaining interest from investors and clinicians. Injectable therapies require regular self-administration, fueling demand for pill-based alternatives.
As a result, pharmaceutical companies are investing heavily in oral programs. This trend reflects broader efforts to improve treatment access and patient adherence. The Food and Drug Administration approved an oral version of Novo Nordisk’s Wegovy in late 2025. This medication is meant for long-term weight management in specific medical situations.
Shortly after, regulators approved Eli Lilly’s Foundayo for adults with obesity. These approvals indicate a growing regulatory pathway for oral therapies. Given this momentum, investment activity in this area extends beyond just one company. Corxel Pharmaceuticals recently finished a two-hundred and eighty-seven million dollar Series D1 financing round.
The company plans to use these funds to speed up its own oral therapy development. Additionally, the capital will support a wider cardiometabolic pipeline. Executives describe the investment as a significant milestone for global development efforts. However, prescription medications are only available through licensed healthcare providers under federal regulation.
Investigational candidates have not yet received regulatory approval and are still being evaluated in clinical trials. Ongoing Phase III data will determine whether the lead candidate moves toward submission. Ultimately, continued investment in the sector shows lasting confidence in oral therapies.
